US FDA approves Bayer's menopause relief drug
Tweet
Share
E-mail
The logo of Bayer Mexico is pictured at the company's plant in Lerma, Mexico November 10, 2022. REUTERS/Henry Romero
(Reuters) -Germany's Bayer said on Friday the U.S. health regulator has approved its drug for menopause relief.
The drug, branded as Lynkuet, is a non-hormonal treatment designed to relieve moderate-to-severe vasomotor symptoms, also known as hot flashes, associated with menopause.
The U.S. Food and Drug Administration's approval was based on three late-stage studies that showed Lynkuet reduced the frequency and severity of hot flashes and eased sleep disturbances in menopausal women.
The regulator had in July extended the review of the drug, but did not raise any concerns regarding its general approvability.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cyclosporiasis cases in US climb to 15,716, CDC says
- Pennsylvania governor signs order imposing new rules to set up AI data centers in state
- US transport regulator resumes review of Union Pacific's proposed Norfolk merger
Create E-mail Alert Related Categories
ReutersRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
